** Shares of Starpharma Holdings fall as much as 2.2% to A$0.091, their lowest level since Sept. 11
** Biopharmaceutical co withdraws marketing authorisation application for SPL7013 nasal spray with Australia's Therapeutic Goods Administration
** SPL7013 is an antiviral spray for protection against COVID-19
** Co says withdrawal after a more than three-year application and review process that consumed significant internal resources
** About 1.5 mln shares change hands, 3 times the 30-day avg of 478,000 shares
** Starpharma down 45.9% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.